Photo of Christine Xu

Christine Xu

Partner and Head of Greater China ECM, Hong Kong SAR

“With 15 years’ experience specialising in Hong Kong IPOs, pre-IPO financing and post-IPO compliance matters, I offer pragmatic advice to issuers, underwriters and financial institutions with my expertise in new economy sectors and the listing regime in Hong Kong, helping clients achieve their strategic objectives in the international capital markets.”

Overview

Education and qualifications

Overview

Christine has extensive experience in Hong Kong initial public offerings, pre-IPO investment, post-IPO equity financing, M&A transactions and post-IPO compliance work, with a focus on advising new economy issuers in the technology, healthcare and consumer sectors.

Christine is highly regarded for her expertise in new economy listings in Hong Kong, including the listings of pre-revenue specialist technology companies under Chapter 18C, pre-revenue biotech companies under Chapter 18A, and issuers with weighted voting rights (WVR) and VIE structures, as well as in dual primary listings, secondary listings and spin-off listings. 

Work highlights

Christine has extensive experience advising:

  • Hong Kong IPOs or listings by way of introduction including Chenqi Technology (also known as Ruqi Mobility), RoboSense Technology, Neusoft Xikang Holdings, JF Wealth, Sipai Health Technology (also known as Medbanks), Kanzhun (also known as BOSS Zhipin), Shanghai Chicmax Cosmetic, Giant Biogene, Dingdang Health Technology Group, Linmon Media, Ping An OneConnect Financial Technology, Recbio Technology, Huitongda Network, UNQ Holdings, Medlive Technology, SciClone Pharmaceuticals, Bilibili, Kuaishou Technology (third HK-listed company with weighted voting rights structure), Harbour BioMed, Archosaur Games, JD.com, XD Inc., Hansoh Pharmaceutical, Maoyan Entertainment, China Kepei Education Group, iDreamSky Technology, Ping An Healthcare and Technology (also known as Ping An Good Doctor), China Literature, China Renaissance Holdings, Legend Holdings, Red Star Macalline Group, Linekong Interactive, China Everbright Bank and China Yongda Automobiles Services.*
  • Technology, media, healthcare and life science and consumer sector companies on M&A transactions including SciClone Pharmaceuticals on its privatisation, Red Star Macalline on the sale of 29.95% equity interests by the controlling shareholder to Xiamen C&D Inc., China Literature on the RMB15.5bn acquisition of New Classics Media and Tencent on its strategic business partnership with JD.com.*
 

 

 
*Denotes experience from previous firm

Education and qualifications

  • University of Oxford, LL.B., 2006
  • The Chinese University of Hong Kong, B.A., 2002
Christine is fluent in English, Mandarin and Cantonese.